Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Pembrolizumab
Keytruda
Not routinely available
SMC (SMC2460)
30/11/2022

Indication

In combination with chemotherapy, for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease. SMC restriction: for use in combination with pa...

In combination with chemotherapy, for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease. SMC restriction: for use in combination with paclitaxel or nab-paclitaxel. Treatment with pembrolizumab is subject to a two-year clinical stopping rule.

Therapeutic Area

Malignant disease and immunosuppression

Status Description

Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines

Formulation

25mg/mL concentrate for solution for infusion

Comments

November 2022 - Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.

Link to Advice

SMC2460

Advice Published

10/10/2022

SMC Submission Type

Full

SMC Status

Restricted